Pricing Log in Create free account
Saturday 17 October 2026 Export FEMY’s income statement to Excel — free account

Femasys Inc.

FEMY Healthcare Medical Instruments & Supplies

Femasys Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 million, up 40.8% from fiscal 2024. In the quarter to June 2026, revenue fell 18.9%, EPS grew 58.4%, free cash flow grew 11.3% and total debt rose 3,369.3%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

1.65 0.09 −5.17%
Market cap
$14.5M
P/E
0.0×
Fwd P/E
−1.4×
Dividend yield
—
F-score
2/9
Altman Z
−10.88
Beneish M
−2.19
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.13
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — 5 — —
Sell — — — — — — — — — — — —
Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 14.54
Revenue 2.30
Net Income (11.77)
Free Cash Flow (18.07)
Net Debt 2.18
Current Ratio 2.14 (at or above 1.5: strong)
Debt/Equity 0.90
P/E ratio 0.00
Fwd P/E (1.35) (negative: loss-making)
P/S ratio 2.41
P/B ratio 1.37
Past 5Y EPS Growth —
This Y EPS Growth 75.78% (at or above 15%: strong)
Next Y EPS Growth 23.13% (at or above 15%: strong)
Next Y revenue growth (9.04%) (below 0%: weak)
Next 5Y EPS Growth 49.37% (at or above 15%: strong)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 3.4×, against a ten-year median of 6.1×; over the ten years it ranged from −11.6× in 2021 to 45.3× in 2021.
P/S against its own 10 years 0.15%
10-year low 10-year high
P/B against its own 10 years 42.52%
10-year low 10-year high
EV/Sales against its own 10 years 12.56%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 22 3 9 1
Receivables 0 0 1 0
Inventory 1 3 6 6
Other 1 1 1 1
23 8 16 8
2023 2024 2025 Q'26
Payables 1 1 2 2
ST’ Debt 0 0 0 0
Other — — — —
3 9 4 4

Compound Annual Growth %

10y 5y 3y
Sales — 17.18% 23.88%
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — 0.00% (27.25%)

Revenue $m

Mar Jun Sep Dec Year
’26 0 0 — — —
’25 0 0 1 1 2
’24 0 0 1 1 2
’23 0 0 0 0 1
’22 0 0 0 0 1
’21 0 0 0 0 1
’20 0 0 0 0 1
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (4) (4) — — —
’25 (5) (4) (5) (4) (19)
’24 (5) (4) (5) (5) (19)
’23 (3) (3) (3) (3) (11)
’22 (3) (2) (3) (3) (11)
’21 (1) (3) (2) (2) (8)
’20 (2) (3) (1) (1) (5)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (4) (4) — — —
’25 (5) (4) (6) (4) (19)
’24 (5) (5) (6) (5) (20)
’23 (3) (3) (3) (3) (11)
’22 (3) (3) (3) (3) (11)
’21 (1) (3) (2) (2) (8)
’20 (2) (3) (1) (1) (5)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 0.00 (1.33) — — —
’25 (4.60) (3.20) (2.00) (0.20) (9.40)
’24 (3.40) (4.20) (4.80) (4.60) (17.00)
’23 (5.00) (4.40) (5.20) (3.80) (18.60)
’22 (4.80) (4.40) (5.00) (4.80) (19.20)
’21 (36.79) (10.40) (3.80) (1.60) (22.40)
’20 (0.18) (31.10) (32.81) — (144.06)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low — — — — — 61.00 11.40 4.96 14.68 6.14

Analyst estimates 2026–2028

Powerpack
High — — — — — 275.00 81.00 95.00 48.00 36.00
People
People Employees — — — — 26 29 36 34 71 54
Revenue/emp, $m — — — 0.00 0.04 0.04 0.03 0.03 0.02 0.04
Income, $m
Income, $m Revenue — — — 1 1 1 1 1 2 2
Gross margin, % — — — (41.89) 70.47 68.60 63.36 64.54 66.55 61.96
EBT — — — (11) (7) (8) (11) (14) (19) (19)
EBT margin, % — — — (1,212.88) (666.08) (638.62) (944.11) (1,328.62) (1,154.44) (812.22)
Net income — 0 — (11) (7) (8) (11) (14) (19) (19)
Depreciation — — — 1 1 1 1 0 0 0
Per share, $
Per share, $ Revenue — — — 0.08 21.62 3.52 2.04 1.39 1.46 1.16
Earnings — — — (0.96) (144.06) (22.40) (19.20) (18.60) (17.00) (9.40)
Cash flow — — — (0.94) (102.77) (23.63) (18.17) (14.67) (17.46) (9.45)
Capex — — — 0.00 (0.66) (0.91) (0.69) (0.19) (0.68) (0.27)
Free cash flow — — — (0.94) (103.43) (24.55) (18.85) (14.85) (18.15) (9.72)
Book value — — — (3.86) (1,079.49) 78.46 25.80 23.86 2.07 2.97
Shares, m — — — 12 0 0 1 1 1 2
Valuation, ×
Valuation, × P/E — — — 0.00 0.00 0.00 0.00 0.00 0.00 0.00
P/S — — — 10.79 10.79 22.19 8.82 14.49 15.04 9.93
P/B — — — 0.00 0.00 0.99 0.70 0.85 10.63 3.88
EV/Sales — — — 60.75 60.75 1.32 (1.81) (1.68) 13.00 8.20
EV/FCF — — — (11.04) (11.04) (0.19) 0.20 0.16 (1.05) (0.98)
Cash, $m
Cash, $m Operating cash flow — — — (11) (5) (8) (11) (11) (19) (19)
Capex — — — (1) 0 0 0 0 (1) (1)
Free cash flow — — — (11) (5) (8) (11) (11) (20) (19)
Balance, $m
Balance, $m Working capital — — — 7 1 24 13 20 (1) 13
Total debt — — — 57 1 0 0 4 0 5
Net debt — — — 50 (2) (25) (13) (17) (3) (4)
Shareholders’ equity — — — (45) (52) 26 15 18 2 6
Returns, %
Returns, % ROA — — — (89.13) (90.91) (41.66) (50.11) (63.81) (93.61) (112.32)
ROIC — — — 0.00 0.00 (303.27) (299.29) (893.46) 0.00 (578.36)
ROE — — — 24.83 13.34 59.12 (54.81) (84.82) (182.18) (455.80)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Femasys Inc. vs peers in Medical Instruments & Supplies (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
HBIO Harvard Bioscience, Inc. $37.8M — (loss-making) — (loss-making) +11.13% (above 0%: growing) n/m −123.43% (below 0%: shrinking) 55.57% (4.30%) Compare
MLSS Milestone Scientific, Inc. $29.6M — (loss-making) — (loss-making) +22.27% (above 0%: growing) n/m +66.68% (above 0%: growing) 67.24% (37.37%) Compare
RVP Retractable Technologies, Inc. $17.6M — (loss-making) 11.1× −31.07% (below 0%: shrinking) n/m +56.67% (above 0%: growing) 2.65% (71.46%) Compare
BNGO Bionano Genomics, Inc. $16.1M — (loss-making) — (loss-making) +21.36% (above 0%: growing) n/m −33.93% (below 0%: shrinking) 52.80% (88.34%) Compare
NXGL NexGel, Inc. $15.9M — (loss-making) — (loss-making) +27.81% (above 0%: growing) n/m −432.32% (below 0%: shrinking) 30.09% (67.96%) Compare
FEMY Femasys Inc. $14.5M — (loss-making) — (loss-making) −18.93% (below 0%: shrinking) n/m +11.29% (above 0%: growing) 57.08% (1,526.79%)
CUPR Cuprina Holdings (Cayman) Limited $11.5M — — — — — — — Compare
RGNT Regentis Biomaterials Ltd. $10.9M — — — — −132.79% (below 0%: shrinking) — — Compare
LUCY Innovative Eyewear, Inc. $7.3M — (loss-making) — +74.46% (above 0%: growing) n/m +9.61% (above 0%: growing) 24.00% (168.73%) Compare
Median of peers $16.0M — — +21.82% — −33.93% 41.45% (69.71%)

All 55 Medical Instruments & Supplies stocks →

Femasys Inc. (FEMY) key facts

  • Strength: Femasys Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 million, up 40.8% from fiscal 2024.
  • Femasys Inc. (FEMY) is a Medical Instruments & Supplies company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, FEMY traded at $1.65, a market capitalization of $14.5 million.
  • Return on equity was −455.8% and debt-to-equity 0.90.
  • Its Piotroski F-score is 2 out of 9 and its Altman Z-score is −10.88 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Femasys Inc. (FEMY) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/FEMY · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com